TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16019088

Group type: EXPERIMENTAL
Intervention: GTN protocol (70 degree tilt, 35 min, CSM at 5 min, 400 microg of glyceryl trinitrate spray administered sublingually at 20 min)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Adenosine protocol (70 degree tilt, 5 min, CSM when blood pressure is stable, adenosine bonus at 150 microg/kg after CSM)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Drug-free protocol (70 degree tilt, 45 min, CSM at 5 and 45 min)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Combined protocols
Number of subjects: 214

Group type: COMPARATOR
Intervention: Conventional management or ILR implantation (for patients without a definite indication for immediate cardiac pacing)
Number of subjects: 214
Study: 12269767

Group type: EXPERIMENTAL
Intervention: Routine cancer screening (mammograms and Pap tests)
Number of subjects: 0
Study: 10566612

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 5156

Group type: COMPARATOR
Intervention: Single-agent chemotherapy
Number of subjects: 5156

Group type: EXPERIMENTAL
Intervention: Paclitaxel + carboplatin
Number of subjects: 5156

Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 5156

Group type: COMPARATOR
Intervention: Single agents (platinum analog or vinorelbine)
Number of subjects: 5156
Study: 8807070

Group type: EXPERIMENTAL
Intervention: Trovafloxacin 50 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Trovafloxacin 100 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Trovafloxacin 200 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Trovafloxacin (all doses)
Number of subjects: 39
Study: 1391670

Group type: EXPERIMENTAL
Intervention: Piracetam (4,800 mg/d for three months)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 3890789

Group type: EXPERIMENTAL
Intervention: Tobramycin sulfate plus ticarcillin disodium (TT)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Moxalactam plus ticarcillin disodium (MT)
Number of subjects: 220
Study: 30578103

Group type: EXPERIMENTAL
Intervention: Quantitative arm
Number of subjects: 688

Group type: COMPARATOR
Intervention: Verbal arm
Number of subjects: 688
Study: 29056498

Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 133

Group type: COMPARATOR
Intervention: GlideScope
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: All devices
Number of subjects: 133
Study: 26826975

Group type: EXPERIMENTAL
Intervention: Weight Bias Internalization Scale (WBIS)
Number of subjects: 90
Study: 24663481

Group type: EXPERIMENTAL
Intervention: Polypropylene mesh (group A)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard abdominal wall closure (group B)
Number of subjects: 160
Study: 22134512

Group type: EXPERIMENTAL
Intervention: Late course accelerated hyperfractionated radiotherapy (LCAF)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventionally fractionated radiotherapy (CF)
Number of subjects: 200
Study: 20493532

Group type: EXPERIMENTAL
Intervention: Zinc supplementation with imipramine treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo supplementation with imipramine treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Imipramine treatment (with or without zinc supplementation)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Imipramine treatment (with zinc supplementation)
Number of subjects: 60
Study: 18064443

Group type: EXPERIMENTAL
Intervention: Higher-intensity, individualized (HI) treadmill training group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lower‐intensity, generalized (LG) treadmill training group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 16134043

Group type: EXPERIMENTAL
Intervention: Aggressive behavior problems with deviant peer affiliation or low parental monitoring
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Aggressive behavior problems with co-occurring depressive symptoms
Number of subjects: 582
Study: 12236844

Group type: EXPERIMENTAL
Intervention: 0.2 mg moxonidine alone
Number of subjects: 6

Group type: COMPARATOR
Intervention: 400 mg quinidine sulphate with 0.2 mg moxonidine
Number of subjects: 6
Study: 10416909

Group type: EXPERIMENTAL
Intervention: Passing a daily screen of weaning parameters
Number of subjects: 300
Study: 9419612

Group type: EXPERIMENTAL
Intervention: 40 ml iohexol
Number of subjects: 99

Group type: COMPARATOR
Intervention: 40 ml ioxaglate
Number of subjects: 99
Study: 1376721

Group type: EXPERIMENTAL
Intervention: Pattern-reversal electroretinograms (ERGs)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pattern-reversal ERG acuity ratings
Number of subjects: 20
Study: 4030190

Group type: EXPERIMENTAL
Intervention: Individual weight training program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Team training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Soccer training alone (Control)
Number of subjects: 0
Study: 31093764

Group type: EXPERIMENTAL
Intervention: Exercise (50 min of treadmill walking at 5.0 km/h before the evening meal)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (50 min of sitting)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Exercise (50 min of treadmill walking)
Number of subjects: 80
Study: 29471381

Group type: EXPERIMENTAL
Intervention: Vedolizumab (VDZ/VDZ)
Number of subjects: 461

Group type: COMPARATOR
Intervention: Placebo (VDZ/PBO)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Prior failure of antibiotic therapy
Number of subjects: 461
Study: 26983548

Group type: EXPERIMENTAL
Intervention: Memantine (5-15 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 25248944

Group type: EXPERIMENTAL
Intervention: Nurse-led titration (NLT) clinic
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 28
Study: 22304745

Group type: EXPERIMENTAL
Intervention: Ceramic ball attachments (20 subjects)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Titanium ball attachments (20 subjects)
Number of subjects: 40
Study: 20919481

Group type: EXPERIMENTAL
Intervention: Physical exercise program (duration: 18 to 22 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 22
Study: 18036357

Group type: EXPERIMENTAL
Intervention: Modified glucose-insulin-potassium (GIK) regimen (insulin 2.5 U/hour, dextrose and potassium titrated to prevent hyperglycemia)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal saline solution and potassium (controls)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Modified glucose-insulin-potassium (GIK) regimen
Number of subjects: 32
Study: 16275185

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SESs)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Bare metal stents (BMSs)
Number of subjects: 74
Study: 11898063

Group type: EXPERIMENTAL
Intervention: 10 mg/d of alendronate for 10 weeks (A)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 20 mg/d of alendronate for 5 weeks (B)
Number of subjects: 66

Group type: COMPARATOR
Intervention: No treatment (C)
Number of subjects: 66
Study: 10473875

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 0
Study: 7485937

Group type: EXPERIMENTAL
Intervention: Patient-Controlled Epidural Analgesia (PCEA)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Midwife-Administered Intermittent Bolus (IB) Epidural Analgesia
Number of subjects: 167
Study: 2097716

Group type: EXPERIMENTAL
Intervention: Gentamicin or netilmicin given by once daily or thrice daily injections
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Estimated creatinine clearance
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conventional monitoring of aminoglycoside treatment
Number of subjects: 60
Study: 421548

Group type: EXPERIMENTAL
Intervention: High-nicotine cigarette (2.6 mg nicotine, 4.5 vol percent CO)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-nicotine cigarette (0.1 mg nicotine, 1.1 vol percent CO)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cigar (not inhaled)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-nicotine cigarette after beta blocker
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inhalation of CO
Number of subjects: 10
Study: 30856095

Group type: EXPERIMENTAL
Intervention: Customary cosmetic usage score
Number of subjects: 2072
Study: 27228145

Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 83

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 83
Study: 25783757

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 23452521

Group type: EXPERIMENTAL
Intervention: 10-second methylprednisolone injection
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 30-second methylprednisolone injection
Number of subjects: 25
Study: 20980399

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 1410

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 1410

Group type: EXPERIMENTAL
Intervention: Routine physical check-ups (out-of-pocket)
Number of subjects: 1410

Group type: EXPERIMENTAL
Intervention: Stage at diagnosis of lung cancer
Number of subjects: 1410

Group type: COMPARATOR
Intervention: Betel-nut consumption
Number of subjects: 1410
Study: 19474132

Group type: EXPERIMENTAL
Intervention: Skim milk (600 mL; 25 g protein, 36 g lactose, <1 g fat; 1062 kJ)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Fruit drink (600 mL; <1 g protein, 63 g sugar, <1 g fat; approximately 1062 kJ)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Skim milk
Number of subjects: 34

Group type: COMPARATOR
Intervention: Fruit drink
Number of subjects: 34
Study: 17983369

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil 10 mg
Number of subjects: 501

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study: 14975536

Group type: EXPERIMENTAL
Intervention: Positive rapid troponin I assay
Number of subjects: 4447

Group type: EXPERIMENTAL
Intervention: Negative rapid troponin I assay
Number of subjects: 4447

Group type: EXPERIMENTAL
Intervention: Troponin T elevation (>0.1 microg/l)
Number of subjects: 4447

Group type: EXPERIMENTAL
Intervention: Troponin T results (>0.1 vs. < or =0.1 microg/l)
Number of subjects: 4447
Study: 11581544

Group type: EXPERIMENTAL
Intervention: Home-based walking exercise program with structured coaching
Number of subjects: 31
Study: 9039853

Group type: EXPERIMENTAL
Intervention: Ozone (O3) exposure at 0.24 ppm for 4 hours
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (clean air) exposure for 4 hours
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ozone (O3) exposure for 4 hours
Number of subjects: 19
Study: 7950335

Group type: EXPERIMENTAL
Intervention: 0.5g imipenem infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1g imipenem infusion
Number of subjects: 10
Study: 3652464

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31813637

Group type: EXPERIMENTAL
Intervention: Ixekizumab Q4W (80 mg every 4 weeks)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Ixekizumab Q2W (80 mg every 2 weeks)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Ixekizumab Q4W and Q2W groups
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Ixekizumab Q4W
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 303
Study: 28114846

Group type: EXPERIMENTAL
Intervention: 400 mg progesterone pessaries, twice daily, started in the luteal phase and continued after a positive pregnancy test till 28 weeks of gestation
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo, twice daily, started in the luteal phase and continued after a positive pregnancy test till 28 weeks of gestation
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: 400 mg progesterone pessaries
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study: 27653798

Group type: EXPERIMENTAL
Intervention: ∆SVC (superior vena cava diameter)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: ∆VmaxAo (maximal Doppler velocity in left ventricular outflow tract)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: ∆IVC (inferior vena cava diameter)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: ∆PP (pulse pressure variations)
Number of subjects: 540
Study: 26643116

Group type: EXPERIMENTAL
Intervention: 7 days high dose primaquine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 14 days high dose primaquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weekly primaquine doses for 8 weeks (for G6PD deficient patients)
Number of subjects: 0
Study: 23294390

Group type: EXPERIMENTAL
Intervention: Nutrition and exercise education, coping skills training, and exercise intervention
Number of subjects: 716
Study: 20736505

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily for at least 2 weeks
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily for at least 2 weeks
Number of subjects: 87

Group type: COMPARATOR
Intervention: Baseline comparison between omeprazole and rabeprazole groups
Number of subjects: 87

Group type: COMPARATOR
Intervention: Post-treatment comparison between omeprazole and rabeprazole groups
Number of subjects: 87
Study: 18414368

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 69

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 69
Study: 15886723

Group type: COMPARATOR
Intervention: 20 mg/day racemic fluoxetine
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 80 mg/day R-fluoxetine
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 120 mg/day R-fluoxetine
Number of subjects: 13
Study: 12818939

Group type: EXPERIMENTAL
Intervention: Rofecoxib (1 mg/kg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 10912700

Group type: EXPERIMENTAL
Intervention: Gentamicin therapy administered transtympanically
Number of subjects: 48

Group type: COMPARATOR
Intervention: Stable Ménière's disease control group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal-hearing control group
Number of subjects: 48
Study: 8860713

Group type: EXPERIMENTAL
Intervention: LDL apheresis
Number of subjects: 47

Group type: COMPARATOR
Intervention: Lipid-lowering drugs
Number of subjects: 47
Study: 1536588

Group type: COMPARATOR
Intervention: Vancomycin and gentamicin
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Vancomycin and aztreonam
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 81
Study: 6366725

Group type: EXPERIMENTAL
Intervention: T4 therapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31574237

Group type: EXPERIMENTAL
Intervention: Nonoperative treatment in patients aged ≥50 years
Number of subjects: 28546

Group type: EXPERIMENTAL
Intervention: Hormonal contraceptives in women <50 years
Number of subjects: 28546

Group type: EXPERIMENTAL
Intervention: Previous VTE history
Number of subjects: 28546

Group type: EXPERIMENTAL
Intervention: Overall incidence of symptomatic VTE
Number of subjects: 28546

Group type: EXPERIMENTAL
Intervention: Incidence rates of VTE
Number of subjects: 28546
Study: 30212948

Group type: EXPERIMENTAL
Intervention: Rational Emotive Behavior Therapy (REBT) intervention for 12 weeks and a follow-up program for 2 weeks
Number of subjects: 86

Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 86
Study: 27465076

Group type: EXPERIMENTAL
Intervention: Intragastric balloon (IGB) therapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 29
Study: 24241327

Group type: EXPERIMENTAL
Intervention: Groin masses (likely hernias)
Number of subjects: 3645

Group type: EXPERIMENTAL
Intervention: Need for health care
Number of subjects: 3645

Group type: EXPERIMENTAL
Intervention: Underwent a procedure
Number of subjects: 3645

Group type: EXPERIMENTAL
Intervention: Barriers to care
Number of subjects: 3645

Group type: EXPERIMENTAL
Intervention: Disability assessment
Number of subjects: 3645
Study: 22038680

Group type: EXPERIMENTAL
Intervention: Rectal balloon training (RBT) with pelvic floor muscle training (PFMT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Pelvic floor muscle training (PFMT) alone
Number of subjects: 80
Study: 19852282

Group type: EXPERIMENTAL
Intervention: Shengjing Capsule at a dose of 1.6 g tid for 12 weeks
Number of subjects: 270

Group type: COMPARATOR
Intervention: Vit E at 50 mg tid for 12 weeks
Number of subjects: 270
Study: 17156137

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg twice daily
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study: 16170935

Group type: EXPERIMENTAL
Intervention: Real-world warnings presented immediately after reading
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Real-world warnings presented after a delay
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Fabricated warnings inconsistent with real-world knowledge
Number of subjects: 2
Study: 11950380

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0
Study: 10519449

Group type: EXPERIMENTAL
Intervention: Gasec-40 Gastrocaps (40 mg daily for 5 days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Antra 40 (40 mg daily for 5 days)
Number of subjects: 28
Study: 7500507

Group type: EXPERIMENTAL
Intervention: Step II Diet and lovastatin (40 mg daily) plus colestipol (30 g daily)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Minimal LDL‐C reduction
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Substantial LDL‐C reduction
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo (plus colestipol if LDL‐C > 90th percentile)
Number of subjects: 146
Study: 1789528

Group type: EXPERIMENTAL
Intervention: Simvastatin (10 or 20 mg once a day, with a doubling of the dosage at week 6 if LDL-cholesterol level remained above 1.40 g/l)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bezafibrate (600 mg 3 times a day, with a doubling of the dosage at week 6 if LDL-cholesterol level remained above 1.40 g/l)
Number of subjects: 24
Study: 6948542

Group type: EXPERIMENTAL
Intervention: Antihypertensive drug treatment
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: High suspiciousness and high pretreatment symptom scores
Number of subjects: 69
Study: 30715997

Group type: EXPERIMENTAL
Intervention: Buparlisib 100 mg once daily on a continuous 28-day schedule (cohort 1)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Buparlisib 100 mg once daily on a continuous 28-day schedule (cohort 2)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Buparlisib 100 mg once daily on a continuous 28-day schedule
Number of subjects: 65
Study: 29488430

Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation (EBL)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Optimized dose of PPI (Control)
Number of subjects: 150
Study: 25567566

Group type: EXPERIMENTAL
Intervention: Planned Cesarean Section (PCS)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Planned Vaginal Delivery (PVD)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Pediatric assessment for twins B born by PVD
Number of subjects: 185
Study: 25257046

Group type: EXPERIMENTAL
Intervention: Intralesional cryotherapy using an argon gas-based system (Seednet)
Number of subjects: 25
Study: 21805109

Group type: EXPERIMENTAL
Intervention: Stepwise clamping (3, 6, 12, and 24 hours per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Straightforward clamping
Number of subjects: 40
Study: 19602758

Group type: EXPERIMENTAL
Intervention: Oral drotaverine (80 mg) plus mefenamic acid (250 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Paracervical block with 1% lignocaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intravenous sedation with diazepam
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oral drotaverine plus mefenamic acid
Number of subjects: 120
Study: 17785361

Group type: EXPERIMENTAL
Intervention: Supraphysiological GH therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15189751

Group type: EXPERIMENTAL
Intervention: TLA 0.5% solution once daily
Number of subjects: 332

Group type: COMPARATOR
Intervention: TIM 0.5% ophthalmic solution twice daily
Number of subjects: 332
Study: 11754786

Group type: EXPERIMENTAL
Intervention: 6 Fr Angio-Seal device (group A; n = 75)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Manual compression (group B; n = 75)
Number of subjects: 150
Study: 9517532

Group type: EXPERIMENTAL
Intervention: Interferon (3-6 MIU three times a week for 6 months)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 25
Study: 7905369

Group type: EXPERIMENTAL
Intervention: Propafenone plus quinidine sulfate (60 mg orally every 8 hours)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Propafenone plus placebo
Number of subjects: 9
Study: 2577015

Group type: EXPERIMENTAL
Intervention: Nifedipine sublingual 10-20 mg alone (group I, n = 19)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nifedipine sublingual 10-20 mg associated with furosemide and clonidine (group II, n = 29)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nifedipine (both groups)
Number of subjects: 48
Study: 186089

Group type: EXPERIMENTAL
Intervention: Thymoxamine (150 mg i.v.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no thymoxamine)
Number of subjects: 0
Study: 31218354

Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg b.i.d.
Number of subjects: 10779

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10779
Study: 28207549

Group type: EXPERIMENTAL
Intervention: 60° angled stylet
Number of subjects: 140

Group type: COMPARATOR
Intervention: 90° angled stylet
Number of subjects: 140
Study: 25181019

Group type: EXPERIMENTAL
Intervention: Eletriptan
Number of subjects: 20

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 20
Study: 23085743

Group type: EXPERIMENTAL
Intervention: Daptomycin 4 mg/kg once daily for 7-14 days
Number of subjects: 111

Group type: COMPARATOR
Intervention: Vancomycin 1 g twice daily for 7-14 days
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 111

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 111